# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

C. Manufacturer and Instrument Name: Sysmex Corporation; Sysmex CS-5100

# D. Type of Test or Tests Performed:

Quantitative coagulation tests: Prothrombin Time (PT) seconds; Prothrombin Time (PT) INR; Activated Partial Thromboplastin Time (APTT); Fibrinogen; Antithrombin and Ddimer

# E. System Descriptions:

# 1. Device Description:

The Sysmex CS-5100 is a fully automated blood coagulation instrument for in vitro diagnostic use in clinical laboratories. The instrument utilizes clotting, chromogenic, and immunoassay methods to analyze venous plasma samples collected in $3 . 2 \%$ sodium citrate. The instrument is capable of measuring the assays in a normal mode and a microsample mode. Results are displayed on the Information Processing Unit (IPU) screen and can be printed on external printers or transmitted to a host computer.

# 2. Principles of Operation:

The Sysmex CS-5100 is an automated blood coagulation instrument which can analyze samples using clotting, chromogenic and immunoassay methods. It performs testing analysis using mechanical, hydraulic, and electrical systems. The instrument uses associated reagents, controls, calibrators, and consumable materials to perform Prothrombin Time (PT) seconds and PT INR, Activated Partial Thromboplastin Time (APTT), Fibrinogen, Antithrombin, and D-dimer.

<table><tr><td colspan="3" rowspan="1">Sysmex CS-5100 Analysis Principles</td></tr><tr><td colspan="1" rowspan="1">Reagent</td><td colspan="1" rowspan="1">Application</td><td colspan="1" rowspan="1">Methodology</td></tr><tr><td colspan="1" rowspan="2">Dade® Innovin®</td><td colspan="1" rowspan="1">PT, Prothrombin Time(seconds)</td><td colspan="1" rowspan="1">Clotting</td></tr><tr><td colspan="1" rowspan="1">PT, Prothrombin Time (INR)</td><td colspan="1" rowspan="1">Clotting, calculated</td></tr><tr><td colspan="1" rowspan="1">Dade® Actin® FSL</td><td colspan="1" rowspan="1">APTT, Activated PartialThromboplastin Time</td><td colspan="1" rowspan="1">Clotting</td></tr><tr><td colspan="1" rowspan="1">Dade® Thrombin Reagent</td><td colspan="1" rowspan="1">Fibrinogen quantitation</td><td colspan="1" rowspan="1">Clotting</td></tr><tr><td colspan="1" rowspan="1">INNOVANCE®Antithrombin</td><td colspan="1" rowspan="1">Antithrombin quantitation</td><td colspan="1" rowspan="1">Chromogenic</td></tr><tr><td>INNOVANCE® D-Dimer</td><td>D-dimer quantitation</td><td>Immuno-chemical</td></tr></table>

Clotting method: Turbidity changes when fibrinogen is transformed into fibrin. This turbidity change is optically detected.   
Chromogenic method: Process of color emission by a chromogenic synthetic   
substrate; light absorbance change.   
Immunoassay method: process of antibody-sensitive reagent reacting with antibodies; light absorbance change.

3. Modes of Operation:

Does the applicant’s device contain the ability to transmit data to a computer, webserver, or mobile device?

Yes ___X_____ or No

Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?

Yes or No _ _X

4. Specimen Identification: Manual or barcode

5. Specimen Sampling and Handling: Automatic pipetting of a specimen in a normal mode and in a micro mode

6. Calibration: Calibration is an automated function of the Sysmex CS-5100 coagulation analyzer. Reagents that require calibration are described in the reagent package insert.

7. Quality Control: The analyzer has two types of control methods: X-Bar control and L-J control.

8. Software:

FDA has reviewed applicant’s Hazard Analysis and Software Development processes for this line of product types:

Yes____X_ ___ or No_

# F. Regulatory Information:

1. Regulation section:

21 CFR 864.5425, Multipurpose system for in vitro coagulation studies

2. Classification: Class II

3 Product code: JPA, System, Multipurpose for In Vitro Coagulation Studies

4. Panel: 81 Hematology

# G. Intended Use:

1. Indication(s) for Use:

Intended use(s):

The Sysmex CS-5100 is a fully automated blood coagulation analyzer intended for in vitro diagnostic use using plasma collected from venous blood samples in $3 . 2 \%$ sodium citrate tubes to analyze clotting, chromogenic and immunoassay methods in the clinical laboratory.

For determination of:

• Prothrombin Time (PT) seconds and PT INR with Dade $\textsuperscript { \textregistered }$ Innovin $\textsuperscript { \textregistered }$   
• Activated Partial Thromboplastin Time (APTT) with Dade $\textsuperscript { \textregistered }$ Actin $\textsuperscript { \textregistered }$ FSL   
• Fibrinogen (Fbg) with Dade $\textsuperscript { \textregistered }$ Thrombin Reagent   
• Antithrombin (AT) with INNOVANCE $\textsuperscript { \textregistered }$ Antithrombin   
• D-dimer with INNOVANCE $\textsuperscript { \textregistered }$ D-Dimer

The performance of this device has not been established in neonate and pediatric patient populations.

2. Special Conditions for Use Statement(s): For prescription use only

# H. Substantial Equivalence Information:

1. Predicate Device Name(s) and 510(k) numbers: Sysmex $\textsuperscript { \textregistered }$ Automated Coagulation Analyzer CA-1500; K011235

# 2. Comparison with Predicate Device:

<table><tr><td rowspan=1 colspan=3>Similarities</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DeviceSysmex CS-5100</td><td rowspan=1 colspan=1>PredicateSysmex® CA-1500</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Fully automated blood plasmacoagulation analyzer for invitro diagnostic use in clinicallaboratories</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>3.2% sodium citrate venousplasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Application type</td><td rowspan=1 colspan=1>Clotting: PT, APTT, andFibrinogenChromogenic: ATImmunochemical: D-dimer</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Operating principle- Chromogenic</td><td rowspan=1 colspan=1>Antithrombin at 405 nm</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sampling mode</td><td rowspan=1 colspan=1>Normal and micro mode</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Light source- Chromogenic- Immunochemical</td><td rowspan=1 colspan=1>Halogen lamp</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Specimen processing</td><td rowspan=1 colspan=1>Automatic pipetting anddilution</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>STAT testing</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Bar code reader</td><td rowspan=1 colspan=1>Sample and reagent</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Random access</td><td rowspan=1 colspan=1>Yes</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Differences</td></tr><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>DeviceSysmex CS-5100</td><td rowspan=1 colspan=1>PredicateSysmex® CA-1500</td></tr><tr><td rowspan=1 colspan=1>Operating principle- Clotting- Immunochemical</td><td rowspan=1 colspan=1>PT, APTT at 660 and 800 nmFIB at 405 nmD-dimer at 660 nm</td><td rowspan=1 colspan=1>PT, APTT, FIB at 660 nmD-dimer at 800 nm</td></tr><tr><td rowspan=1 colspan=1>Light source- Clotting</td><td rowspan=1 colspan=1>Halogen lamp</td><td rowspan=1 colspan=1>Light emitting diode</td></tr><tr><td rowspan=1 colspan=1>Probes- Sample- Reagent</td><td rowspan=1 colspan=1>2 probes3 probes</td><td rowspan=1 colspan=1>1 probe1 probe</td></tr><tr><td rowspan=1 colspan=1>Cap piercing</td><td rowspan=1 colspan=1>Cap piercer</td><td rowspan=1 colspan=1>Cap piercerNon-cap piercer</td></tr><tr><td rowspan=1 colspan=1>Pipetting capabilities- Sample probe- Reagent probe</td><td rowspan=1 colspan=1>4 - 270 μL20 - 200 μL</td><td rowspan=1 colspan=1>5 - 450 μL3 - 200 μL</td></tr><tr><td rowspan=1 colspan=1>Bidirectional interfacecommunication protocols</td><td rowspan=1 colspan=1>CA-, ASTM-, CS-Protocol</td><td rowspan=1 colspan=1>CA-, ASTM-Protocol</td></tr></table>

# I. Special Control/Guidance Document Referenced (if applicable):

• CLSI EP28-A3c Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory CLSI EP05-A2 Evaluation of Precision Performance of Quantitative Measurement Methods   
• CLSI EP6-A2 Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach   
• CLSI EP7-A2 Interference Testing in Clinical Chemistry   
• CLSI EP17-A2 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures   
• CLSI EP9-A3 Measurement Procedure Comparison and Bias Estimation Using Patient Samples   
• CLSI EP25-A Evaluation of Stability of In Vitro Diagnostic Reagents   
• CLSI H59-A Quantitative D-dimer for the Exclusion of Venous Thromboembolic Disease   
• CLSI AUTO11-A2 Information Technology Security of In Vitro Diagnostic Instruments and Software Systems; Approved Standard

# J. Performance Characteristics:

1. Analytical Performance:

a. Accuracy:

i. Method comparison with predicate device:

Method comparison studies were conducted at three external sites in the United States. Subjects over 18 years of age were enrolled. At each site, a minimum of 100 samples were included for a total of n ${ \ge } 3 0 0$ . Samples were tested on both the predicate device (Sysmex $\textsuperscript { \textregistered }$ CA-1500) and the candidate device (Sysmex CS-5100) in random order. The study was designed according to CLSI EP9-A3.

<table><tr><td rowspan=1 colspan=5>Method Comparison Summary Table, Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>Application(measuring interval)</td><td rowspan=1 colspan=1>Site 01</td><td rowspan=1 colspan=1>Site 02</td><td rowspan=1 colspan=1>Site 03</td><td rowspan=1 colspan=1>Sites Combined</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Time(seconds)using Dade® Innovin®(8.7 - 90.0 seconds)</td><td rowspan=1 colspan=1>N=126y = 1.000x + 0.350r = 0.997</td><td rowspan=1 colspan=1>N=219y = 1.000x + 0.000r = 0.999</td><td rowspan=1 colspan=1>N=136y = 0.986x + 0.396r = 0.999</td><td rowspan=1 colspan=1>N=469y = 1.000x + 0.100r = 0.998</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Time(INR)using Dade® Innovin®(0.93 - 8.00 INR)</td><td rowspan=1 colspan=1>N=123y = 1.044x - 0.038r = 0.997</td><td rowspan=1 colspan=1>N=218y = 1.029x - 0.037r = 0.999</td><td rowspan=1 colspan=1>N=136y = 1.039x - 0.019r= 0.999</td><td rowspan=1 colspan=1>N=465y = 1.047x - 0.047r=0.999</td></tr></table>

ii. Clinical cut-off: Validation for pulmonary embolism (PE)   

<table><tr><td rowspan=1 colspan=5>Method Comparison Summary Table, Passing-Bablok regression</td></tr><tr><td rowspan=1 colspan=1>Application(measuring interval)</td><td rowspan=1 colspan=1>Site 01</td><td rowspan=1 colspan=1>Site 02</td><td rowspan=1 colspan=1>Site 03</td><td rowspan=1 colspan=1>Sites Combined</td></tr><tr><td rowspan=1 colspan=1>Activated PartialThromboplastin Timeusing Dade® Actin®FSL(20.0  139.0 seconds)</td><td rowspan=1 colspan=1>N=130y = 1.029x - 1.083r = 0.994</td><td rowspan=1 colspan=1>N=221y = 1.018x - 1.190r = 0.998</td><td rowspan=1 colspan=1>N=131y = 1.027x - 1.217r = 0.994</td><td rowspan=1 colspan=1>N=466y = 1.026x - 1.315r = 0.996</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen quantitationusing Dade® ThrombinReagent(50 - 860 mg/dL)</td><td rowspan=1 colspan=1>N=148y = 1.052x - 4.866r = 0.994</td><td rowspan=1 colspan=1>N=112y = 1.026x + 6.869r = 0.996</td><td rowspan=1 colspan=1>N=134y = 0.982x + 9.800r = 0.998</td><td rowspan=1 colspan=1>N=368y = 1.018x + 4.633r = 0.995</td></tr><tr><td rowspan=1 colspan=1>Antithrombinquantitationusing INNOVANCE®Antithrombin(9.0 - 128.0% of norm)</td><td rowspan=1 colspan=1>N=136y = 0.991x - 0.459r = 0.996</td><td rowspan=1 colspan=1>N=126y = 0.960x + 1.726r = 0.993</td><td rowspan=1 colspan=1>N=128y = 0.985x - 0.362r = 0.997</td><td rowspan=1 colspan=1>N=381y = 0.980x + 0.222r = 0.996</td></tr><tr><td rowspan=1 colspan=1>D-dimer quantitationusing INNOVANCE®D-Dimer(0.19 - 35.20 mg/L FEU)</td><td rowspan=1 colspan=1>N=146y = 1.060x - 0.016r= 0.997</td><td rowspan=1 colspan=1>N=112y = 1.000x - 0.030r = 0.997</td><td rowspan=1 colspan=1>N=118y = 1.000x + 0.000r = 0.998</td><td rowspan=1 colspan=1>N=361y = 1.021x + 0.007r = 0.996</td></tr></table>

The INNOVANCE $\textsuperscript { \textregistered }$ D-Dimer assay was evaluated internally on the Sysmex CS5100 coagulation analyzer. The samples were collected from a multi-center study including 15 sites in the United States and 4 sites in Germany to validate the exclusion of PE using frozen specimens collected prospectively from 1,930 consecutive outpatients who presented to the emergency or ambulatory department with suspected PE. Exclusion of 96 subjects yielded in a total of 1,834 evaluable subjects. All centers used the same clinical protocol following the recommendations of CLSI H59-A “Quantitative D-Dimer for the Exclusion of Venous Thromboembolic Disease.”

The Wells’ score were used to estimate a high, intermediate or low pre-test probability (PTP) of PE for all subjects. Patients with a high PTP score were excluded from the study. Patient samples were tested with the INNOVANCE $\textsuperscript { \textregistered }$ D-Dimer assay and results were compared to a cutoff value of $0 . 5 0 \mathrm { m g / L }$ FEU. A D-dimer result ${ \geq } 0 . 5 0 \ \mathrm { m g / L }$ FEU was considered positive. A D-dimer result $< 0 . 5 0 \ \mathrm { m g / L }$ FEU was considered negative. Patients with a positive D-dimer result were evaluated by imaging methods, e.g. spiral computer tomography (CT) and/or ventilation/perfusion (VQ) scan. Patients with a negative D-dimer result underwent imaging at the physician’s discretion. All patients with a negative diagnosis of PE were followed for three months to evaluate potential development of PE. Patients with unobtainable follow-up data were excluded from analysis yielding a total of 1,467 patients for final analysis. The overall prevalence of PE in those patients available for final analysis was $6 . 9 \%$ (101/1467) with $6 . 0 \%$ in the U.S. population and $3 7 . 2 \%$ in the German outside U.S. (OUS) population. The instrument-specific sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) with lower bound (LCL) of two-sided $9 5 \%$ confidence interval were obtained with the INNOVANCE $^ \mathrm { \textregistered }$ D-Dimer clinical cut-off of $0 . 5 0 \mathrm { m g / L }$ FEU.

<table><tr><td rowspan=2 colspan=3>U.S.</td><td rowspan=1 colspan=3>Reference (Imaging and 3-month follow-up)</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>INNOVANCE® D-</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>83</td><td rowspan=1 colspan=1>616</td><td rowspan=1 colspan=1>699</td></tr><tr><td rowspan=4 colspan=2>Dimer on SysmexCS-5100 System</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>723</td><td rowspan=1 colspan=1>725</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>1339</td><td rowspan=1 colspan=1>1424</td></tr></table>

Sensitivity $\% = 9 7 . 6$ 95% LCL = 91.8   
Specificity $\% = 5 4 . 0$ 95% LCL = 51.3   
NPV $\% = 9 9 . 7$ 95% LCL = 99.0   
$\mathrm { N P V ^ { * } ~ } \% = 9 9 . 2$ 95% LCL = 97.3   
PPV $\% = 1 1 . 9$ 95% LCL = 9.7   
$\mathrm { P P V ^ { \ast } } ~ \% = 2 7 . 2$ 95% LCL = 23.0   
Sensitivity $\% = 1 0 0 . 0$ 95% LCL = 79.4   
Specificity $\% = 8 1 . 5$ 95% LCL = 61.9   
NPV $\% = 1 0 0 . 0$ 95% LCL = 85.1   
$\mathrm { N P V ^ { * } \ ^ { 0 } } _ { 0 } = \ 1 0 0 . 0$ 95% LCL = 95.1   
PPV $\% = 7 6 . 2$ 95% LCL = 54.9   
$\mathrm { P P V ^ { \ast } } ~ \% = 4 8 . 8$ 95% LCL = 26.6

<table><tr><td rowspan=2 colspan=3>OUS</td><td rowspan=1 colspan=3>Reference (Imaging and 3-month follow-up)</td></tr><tr><td rowspan=1 colspan=2>Positive         Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=2>INNOVANCE® D-</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>21</td></tr><tr><td rowspan=4 colspan=2>Dimer on SysmexCS-5100 System</td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>43</td></tr></table>

<table><tr><td rowspan=2 colspan=2>U.S. and OUS</td><td rowspan=1 colspan=3>Reference (Imaging and 3-month follow-up)</td></tr><tr><td rowspan=1 colspan=2>Positive         Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=3 colspan=1>INNOVANCE® D-Dimer on SysmexCS-5100 System</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>621</td><td rowspan=1 colspan=1>720</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>745</td><td rowspan=1 colspan=1>747</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>101</td><td rowspan=1 colspan=1>1366</td><td rowspan=1 colspan=1>1467</td></tr></table>

Sensitivity $\% = 9 8 . 0$ 95% LCL = 93.0 Specificity $\% = 5 4 . 5$ 95% LCL = 51.9 NPV $\% = 9 9 . 7$ 95% LCL = 99.0 $\mathrm { N P V ^ { * } ~ \% } = 9 9 . 4$ 95% LCL = 97.7 PPV $\% = 1 3 . 8$ $9 5 \% \mathrm { L C L } = 1 1 . 4$ $\mathrm { P P V ^ { \ast } } ~ \% = 2 7 . 6$ $9 5 \% \mathrm { L C L } = 2 3 . 5$ \*standardized to a prevalence of $1 5 \%$ iii. Expected values/Reference range:

Clinical studies were performed to quantify reference ranges for the reagent applications for Dade $\textsuperscript { \textregistered }$ Innovin, Dade $\textsuperscript { \textregistered }$ Actin $\textsuperscript { \textregistered }$ FSL, Dade $\textsuperscript { \textregistered }$ Thrombin Reagent, INNOVANCE $\textsuperscript { \textregistered }$ Antithrombin, and INNOVANCE $\textsuperscript { \textregistered }$ D-Dimer. One reagent lot was used for each assay. The reference range is established by calculation of the $9 5 \%$ confidence interval $2 . 5 - 9 7 . 5 $ percentiles.

<table><tr><td rowspan=1 colspan=1>Application</td><td rowspan=1 colspan=1>Reference Ranges Sysmex CS-5100</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Time (seconds) with Dade®Innovin®</td><td rowspan=1 colspan=1>2.5th  97.5th percentile9.6  12.3</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Time (INR) with Dade®Innovin®</td><td rowspan=1 colspan=1>2.5th  97.5th percentile0.93 - 1.15</td></tr><tr><td rowspan=1 colspan=1>Activated Partial Thromboplastin Time(seconds) with Dade® Actin® FSL</td><td rowspan=1 colspan=1>2.5th  97.5th percentile23.9  29.9</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen quantitation with Dade®Thrombin Reagent (mg/dL)</td><td rowspan=1 colspan=1>2.5th  97.5th percentile194 - 448</td></tr><tr><td rowspan=1 colspan=1>Antithrombin quantitation withINNOVANCE® Antithrombin (% of norm)</td><td rowspan=1 colspan=1>2.5th  97.5th percentile82.9 - 121.9</td></tr><tr><td rowspan=1 colspan=1>D-dimer quantitation with INNOVANCE®D-Dimer (mg/L FEU)</td><td rowspan=1 colspan=1>2.5th  97.5th percentile&lt;0.19 - 1.14</td></tr></table>

# b. Precision/Reproducibility:

A 20-day precision study was performed at three clinical sites, one in U.S. and two in Germany. Control materials and plasma samples were used to evaluate the device performance. The study followed the scheme of two runs per day, with two replicates per run at each of the three sites following CLSI EP05-A2. Within-run, between-run, between-day, and total precision within site were calculated.

<table><tr><td colspan="6" rowspan="1">Reproducibility Summary Table, Within-Run</td></tr><tr><td colspan="1" rowspan="1">Application(CR/Clotting time range)</td><td colspan="1" rowspan="1">Sample Range(mean of allsites)</td><td colspan="1" rowspan="1">Site 01Within-Run(%CV)</td><td colspan="1" rowspan="1">Site 02Within-Run(%CV)</td><td colspan="1" rowspan="1">Site 03Within-Run(%CV)</td><td colspan="1" rowspan="1">SitesCombined(%CV)</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time (second)using Dade® Innovin®(8.7 - 90.0 seconds)</td><td colspan="1" rowspan="1">9.27  79.67seconds</td><td colspan="1" rowspan="1">0.64 - 1.85</td><td colspan="1" rowspan="1">0.47 - 0.98</td><td colspan="1" rowspan="1">0.51 - 3.61</td><td colspan="1" rowspan="1">0.59 - 2.35</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time (INR)using Dade® Innovin®(0.93 - 8.00 INR)</td><td colspan="1" rowspan="1">1.02 - 7.76INR</td><td colspan="1" rowspan="1">0.62 - 2.21</td><td colspan="1" rowspan="1">0.45 - 0.92</td><td colspan="1" rowspan="1">0.44 - 1.31</td><td colspan="1" rowspan="1">0.51 - 1.50</td></tr><tr><td colspan="1" rowspan="1">Activated PartialThromboplastin Timeusing Dade® Actin® FSL(20.0  139.0 seconds)</td><td colspan="1" rowspan="1">22.02  123.25seconds</td><td colspan="1" rowspan="1">0.71 - 5.51</td><td colspan="1" rowspan="1">0.51 - 3.05</td><td colspan="1" rowspan="1">0.56 - 2.67</td><td colspan="1" rowspan="1">0.76 - 3.93</td></tr><tr><td colspan="1" rowspan="1">Application(CRR/Clotting time range)</td><td colspan="1" rowspan="1">Sample Range(mean of allsites</td><td colspan="1" rowspan="1">Site 01Within-Run(%CV)</td><td colspan="1" rowspan="1">Site 02Within-Run(%CV)</td><td colspan="1" rowspan="1">Site 03Within-Run(%CV)</td><td colspan="1" rowspan="1">SitesCombined(%CV)</td></tr><tr><td colspan="1" rowspan="1">Fibrinogen quantitationusing Dade ThrombinReagent(50 - 860 mg/dL)</td><td colspan="1" rowspan="1">56.2 - 752.6mg/dL</td><td colspan="1" rowspan="1">1.14 - 6.18</td><td colspan="1" rowspan="1">0.99 - 3.27</td><td colspan="1" rowspan="1">1.41 - 2.72</td><td colspan="1" rowspan="1">1.20 - 420</td></tr><tr><td colspan="1" rowspan="1">Antithrombin quantitationusing INNOVANCE®Antithrombin(9.0 - 128.0% of norm)</td><td colspan="1" rowspan="1">10.17 -119.41% ofnorm</td><td colspan="1" rowspan="1">0.71  2.66</td><td colspan="1" rowspan="1">0.81 - 3.45</td><td colspan="1" rowspan="1">0.97 - 3.13</td><td colspan="1" rowspan="1">0.92 - 3.11</td></tr><tr><td colspan="1" rowspan="1">D-dimer quantitationusing INNOVANCE®D-Dimer(0.19 - 35.20 mg/L FEU)</td><td colspan="1" rowspan="1">0.25 - 33.81mg/L FEU</td><td colspan="1" rowspan="1">0.91 - 2.15</td><td colspan="1" rowspan="1">0.80 - 1.56</td><td colspan="1" rowspan="1">1.27 - 2.51</td><td colspan="1" rowspan="1">1.08 - 2.07</td></tr></table>

CRR: Clinical Reportable Range

<table><tr><td colspan="6" rowspan="1">Reproducibility Summary Table, Between-Run</td></tr><tr><td colspan="1" rowspan="1">Application(CR/Clotting time range)</td><td colspan="1" rowspan="1">Sample Range(mean of allsites</td><td colspan="1" rowspan="1">Site 01Between-Run(%CV)</td><td colspan="1" rowspan="1">Site 02Between-Run(%CV)</td><td colspan="1" rowspan="1">Site 03Between-Run(%CV)</td><td colspan="1" rowspan="1">SitesCombined(%CV)</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time(second)using Dade® Innovin®(8.7 - 90.0 sec)</td><td colspan="1" rowspan="1">9.27  79.67seconds</td><td colspan="1" rowspan="1">0.12 - 1.73</td><td colspan="1" rowspan="1">0.00- 1.15</td><td colspan="1" rowspan="1">0.00 - 1.45</td><td colspan="1" rowspan="1">0.35 - 1.42</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time(INR)using Dade® Innovin®(0.93 - 8.00 INR)</td><td colspan="1" rowspan="1">1.02 - 7.76INR</td><td colspan="1" rowspan="1">0.00-2.05</td><td colspan="1" rowspan="1">0.00 - 1.12</td><td colspan="1" rowspan="1">0.53 - 1.30</td><td colspan="1" rowspan="1">0.25 - 1.37</td></tr><tr><td colspan="1" rowspan="1">Activated PartialThromboplastin Timeusing Dade® Actin® FSL(20.0 - 139.0 sec)</td><td colspan="1" rowspan="1">22.02  123.25seconds</td><td colspan="1" rowspan="1">0.00- 0.97</td><td colspan="1" rowspan="1">0.00-2.50</td><td colspan="1" rowspan="1">0.29 - 2.66</td><td colspan="1" rowspan="1">0.34  2.40</td></tr><tr><td colspan="1" rowspan="1">Fibrinogen quantitationusing Dade® ThrombinReagent(50 - 860 mg/dL)</td><td colspan="1" rowspan="1">56.2  752.6mg/dL</td><td colspan="1" rowspan="1">0.00- 1.25</td><td colspan="1" rowspan="1">0.00-1.07</td><td colspan="1" rowspan="1">0.00 - 1.26</td><td colspan="1" rowspan="1">0.00-0.88</td></tr><tr><td colspan="1" rowspan="1">Antithrombinquantitationusing INNOVANCE®Antithrombin(9.0 - 128.0% of norm)</td><td colspan="1" rowspan="1">10.17 - 119.41%of norm</td><td colspan="1" rowspan="1">0.42 - 1.40</td><td colspan="1" rowspan="1">0.00 - 4.33</td><td colspan="1" rowspan="1">0.94  4.45</td><td colspan="1" rowspan="1">0.78 - 3.73</td></tr><tr><td colspan="1" rowspan="1">D-dimer quantitationusing INNOVANCE® D-Dimer(0.19 - 35.20 mg/L FEU)</td><td colspan="1" rowspan="1">0.25 - 33.81mg/L FEU</td><td colspan="1" rowspan="1">0.33 - 1.18</td><td colspan="1" rowspan="1">0.00-1.50</td><td colspan="1" rowspan="1">0.00- 2.12</td><td colspan="1" rowspan="1">0.30 - 1.61</td></tr><tr><td colspan="6" rowspan="1">Reproducibility Summary Table, Between-Day</td></tr><tr><td colspan="1" rowspan="1">Application(CR/Clotting time range)</td><td colspan="1" rowspan="1">Sample Range(mean of allsites</td><td colspan="1" rowspan="1">Site 01Between-Day(%CV)</td><td colspan="1" rowspan="1">Site 02Between-Day(%CV)</td><td colspan="1" rowspan="1">Site 03Between-Day(%CV)</td><td colspan="1" rowspan="1">SitesCombined(%CV)</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time(seconds)using Dade® Innovin®(8.7 - 90.0 sec)</td><td colspan="1" rowspan="1">9.27 - 79.67seconds</td><td colspan="1" rowspan="1">0.00 - 0.97</td><td colspan="1" rowspan="1">0.00- 0.57</td><td colspan="1" rowspan="1">0.00 - 2.45</td><td colspan="1" rowspan="1">0.17- 1.45</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time(INR)using Dade® Innovin®(0.93 - 8.00 INR)</td><td colspan="1" rowspan="1">1.02 - 7.76INR</td><td colspan="1" rowspan="1">0.00 - 2.81</td><td colspan="1" rowspan="1">0.00 - 0.60</td><td colspan="1" rowspan="1">0.44  2.38</td><td colspan="1" rowspan="1">0.26 - 1.78</td></tr><tr><td colspan="1" rowspan="1">Activated PartialThromboplastin Timeusing Dade® Actin® FSL(20.0 - 139.0 sec)</td><td colspan="1" rowspan="1">22.02  123.25seconds</td><td colspan="1" rowspan="1">0.00 - 3.84</td><td colspan="1" rowspan="1">0.00 - 1.94</td><td colspan="1" rowspan="1">0.00-3.82</td><td colspan="1" rowspan="1">0.11-2.77</td></tr><tr><td colspan="1" rowspan="1">Fibrinogen quantitationusing Dade® ThrombinReagent(50 - 860 mg/dL)</td><td colspan="1" rowspan="1">56.2 - 752.6mg/dL</td><td colspan="1" rowspan="1">0.00 - 1.11</td><td colspan="1" rowspan="1">0.00 - 1.02</td><td colspan="1" rowspan="1">0.00 - 1.11</td><td colspan="1" rowspan="1">0.00-0.74</td></tr><tr><td colspan="1" rowspan="1">Antithrombinquantitationusing INNOVANCE®Antithrombin(9.0  128.0% of norm)</td><td colspan="1" rowspan="1">10.17 - 119.41%of norm</td><td colspan="1" rowspan="1">0.00 - 1.84</td><td colspan="1" rowspan="1">0.00 - 1.62</td><td colspan="1" rowspan="1">0.00-1.18</td><td colspan="1" rowspan="1">0.00 - 1.22</td></tr><tr><td colspan="1" rowspan="1">D-dimer quantitationusing INNOVANCE® D-Dimer(0.19 - 35.20 mg/L FEU)</td><td colspan="1" rowspan="1">0.25 - 33.81mg/L FEU</td><td colspan="1" rowspan="1">1.49 - 5.95</td><td colspan="1" rowspan="1">0.00 - 1.56</td><td colspan="1" rowspan="1">0.85 - 3.19</td><td colspan="1" rowspan="1">1.14 - 3.86</td></tr></table>

<table><tr><td rowspan=1 colspan=3>Reproducibility Summary Table, Site-to-Site</td></tr><tr><td rowspan=1 colspan=1>Application(CRR/Clotting time range)</td><td rowspan=1 colspan=1>Sample Range(mean of all sites)</td><td rowspan=1 colspan=1>SitesCombined(%CV)</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Timeusing Dade® Innovin®(8.7 - 90.0 sec)</td><td rowspan=1 colspan=1>9.27  79.67 seconds</td><td rowspan=1 colspan=1>0.00 - 0.95</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Time (INR)using Dade® Innovin® (0.93 - 8.00 INR)</td><td rowspan=1 colspan=1>1.02 - 7.76 INR</td><td rowspan=1 colspan=1>0.09 - 1.21</td></tr><tr><td rowspan=1 colspan=1>Activated Partial Thromboplastin Timeusing Dade® Actin® FSL(20.0  139.0 sec)</td><td rowspan=1 colspan=1>22.02  123.25 seconds</td><td rowspan=1 colspan=1>0.04 - 5.16</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen quantitationusing Dade® Thrombin Reagent(50 - 860 mg/dL)</td><td rowspan=1 colspan=1>56.2  752.6 mg/dL</td><td rowspan=1 colspan=1>0.97 - 3.96</td></tr><tr><td rowspan=1 colspan=1>Antithrombin quantitationusing INNOVANCE® Antithrombin(9.0 - 128.0% of norm)</td><td rowspan=1 colspan=1>10.17 - 119.41% of norm</td><td rowspan=1 colspan=1>0.85 - 2.88</td></tr><tr><td rowspan=1 colspan=1>D-dimer quantitationusing INNOVANCE® D-Dimer(0.19 - 35.20 mg/L FEU)</td><td rowspan=1 colspan=1>0.25 - 33.81 mg/L FEU</td><td rowspan=1 colspan=1>0.61 - 2.93</td></tr></table>

<table><tr><td rowspan=1 colspan=6>Reproducibility Summary Table, Total CV (Within-Site)</td></tr><tr><td rowspan=1 colspan=1>Application(CRR/Clotting time range)</td><td rowspan=1 colspan=1>SampleRange (meanof all sites)</td><td rowspan=1 colspan=1>Site 01Total Within-Site(%CV)</td><td rowspan=1 colspan=1>Site 02Total Within-Site(%CV)</td><td rowspan=1 colspan=1>Site 03Total Within-Site(%CV)</td><td rowspan=1 colspan=1>SitesCombined(%CV)</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Time(second)using Dade® Innovin®(8.7 - 90.0 sec)</td><td rowspan=1 colspan=1>9.27 - 79.67seconds</td><td rowspan=1 colspan=1>0.82  2.42</td><td rowspan=1 colspan=1>0.52 - 1.39</td><td rowspan=1 colspan=1>1.00-4.17</td><td rowspan=1 colspan=1>0.86 - 2.95</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Time (INR)using Dade® Innovin®(0.93 - 8.00 INR)</td><td rowspan=1 colspan=1>1.02 - 7.76INR</td><td rowspan=1 colspan=1>0.73 - 4.12</td><td rowspan=1 colspan=1>0.49 - 1.36</td><td rowspan=1 colspan=1>0.86-3.00</td><td rowspan=1 colspan=1>0.72 - 2.96</td></tr><tr><td rowspan=1 colspan=1>Activated PartialThromboplastin Timeusing Dade® Actin® FSL(20.0 - 139.0 sec)</td><td rowspan=1 colspan=1>22.02123.25seconds</td><td rowspan=1 colspan=1>0.85 - 6.78</td><td rowspan=1 colspan=1>0.58 - 3.95</td><td rowspan=1 colspan=1>0.72 - 5.37</td><td rowspan=1 colspan=1>1.00-7.45</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen quantitationusing Dade® ThrombinReagent(50 - 860 mg/dL)</td><td rowspan=1 colspan=1>56.2 - 752.6mg/dL</td><td rowspan=1 colspan=1>1.31 - 6.18</td><td rowspan=1 colspan=1>1.29 - 3.52</td><td rowspan=1 colspan=1>1.60 - 2.94</td><td rowspan=1 colspan=1>2.08 - 4.33</td></tr><tr><td rowspan=1 colspan=1>Antithrombinquantitationusing INNOVANCE®Antithrombin(9.0 - 128.0% of norm)</td><td rowspan=1 colspan=1>10.17-119.41% ofnorm</td><td rowspan=1 colspan=1>1.07 - 3.53</td><td rowspan=1 colspan=1>1.17 - 5.53</td><td rowspan=1 colspan=1>1.55  5.44</td><td rowspan=1 colspan=1>1.81 - 5.64</td></tr><tr><td rowspan=1 colspan=1>D-dimer quantitationusing INNOVANCE® D-Dimer(0.19 - 35.20 mg/L FEU)</td><td rowspan=1 colspan=1>0.25 - 33.81mg/L FEU</td><td rowspan=1 colspan=1>2.0 - 6.40</td><td rowspan=1 colspan=1>1.31 - 2.21</td><td rowspan=1 colspan=1>2.16 - 4.58</td><td rowspan=1 colspan=1>2.05 - 5.51</td></tr></table>

c. Linearity:

A linearity study was conducted as described in CLSI EP6-A “Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach” for Fibrinogen, Antithrombin, and D-dimer assays. Linearity is not applicable to noncalibrated assays: PT seconds, PT INR, APTT. Resulting data met pre-established acceptance criteria

<table><tr><td colspan="3" rowspan="1">Linearity and Measuring Range Summary</td></tr><tr><td colspan="1" rowspan="1">Reagent</td><td colspan="1" rowspan="1">Measured Linear Range</td><td colspan="1" rowspan="1">Clinical ReportableRange</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time(seconds)using Dade® Innovin®</td><td colspan="1" rowspan="1">Not applicable</td><td colspan="1" rowspan="1">8.7  90.0 seconds</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time(INR)using Dade® Innovin®</td><td colspan="1" rowspan="1">Not applicable</td><td colspan="1" rowspan="1">0.93 - 8.00 INR</td></tr><tr><td colspan="1" rowspan="1">Activated Partial ThromboplastinTime (seconds)using Dade® Actin® FSL</td><td colspan="1" rowspan="1">Not applicable</td><td colspan="1" rowspan="1">20.0  139.0 seconds</td></tr><tr><td colspan="1" rowspan="1">Fibrinogen quantitation(mg/dL)using Dade® Thrombin Reagent</td><td colspan="1" rowspan="1">40.300 - 1124.000 mg/dL</td><td colspan="1" rowspan="1">50 - 860 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Antithrombin quantitation(% of norm)using INNOVANCE® Antithrombin</td><td colspan="1" rowspan="1">6.280 - 152.300% of norm</td><td colspan="1" rowspan="1">9.0 - 128.0% of norm</td></tr><tr><td colspan="1" rowspan="1">D-dimer quantitation(mg/L FEU)using INNOVANCE® D-Dimer</td><td colspan="1" rowspan="1">0.149 - 50.862 mg/L FEU</td><td colspan="1" rowspan="1">0.19 - 35.20 mg/L FEU</td></tr></table>

# d. Carryover:

# i. Reagent Carryover

Reagent carryover was assessed in-house to ensure there is no contamination from one assay application to another. Washing steps are included between all pipetting steps. The results were evaluated to confirm the absence of any reagent carryover of the applications and results were within the acceptance criteria. All possible carryover events were analyzed for all reagent components for every application of the PT, APTT, Fibrinogen, Antithrombin, and D-dimer quantitation assays.

# ii. Sample Carryover

Sample carryover studies were conducted in-house to evaluate whether a sample could cause contamination by being carried over into the next test. The analyzer’s aspiration and washing of the sample probe between pipetting steps would eliminate the possibility of contamination. Results met predetermined acceptance criteria for PT, APTT, Fibrinogen, Antithrombin, and D-dimer quantitation assays.

# e. Interfering Substances:

i. Interference testing (hemolysis, icterus, and lipemia) to determine the level of optical interference was conducted for each assay.

<table><tr><td colspan="2" rowspan="1"></td><td colspan="4" rowspan="1">Highest Level without Interference</td></tr><tr><td colspan="1" rowspan="1">Reagent</td><td colspan="1" rowspan="1">Pool</td><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">Bilirubin(conjugated)</td><td colspan="1" rowspan="1">Bilirubin(un-conjugated)</td><td colspan="1" rowspan="1">Triglyceride</td></tr><tr><td colspan="1" rowspan="1">Dade® Innovin®(seconds)</td><td colspan="1" rowspan="1">NormalPathological (High)</td><td colspan="1" rowspan="1">1000 mg/dL1000 mg/dL</td><td colspan="1" rowspan="1">40 mg/dL40 mg/dL</td><td colspan="1" rowspan="1">60 mg/dL60 mg/dL</td><td colspan="1" rowspan="1">249 mg/dL234 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Dade® Innovin®(INR)</td><td colspan="1" rowspan="1">NormalPathological (High)</td><td colspan="1" rowspan="1">1000 mg/dL1000 mg/dL</td><td colspan="1" rowspan="1">40 mg/dL30.6 mg/dL</td><td colspan="1" rowspan="1">60 mg/dL60 mg/dL</td><td colspan="1" rowspan="1">218 mg/dL289 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Dade® Actin®FSL</td><td colspan="1" rowspan="1">NormalPathological (High)</td><td colspan="1" rowspan="1">1000 mg/dL1000 mg/dL</td><td colspan="1" rowspan="1">40 mg/dL40 mg/dL</td><td colspan="1" rowspan="1">60 mg/dL60 mg/dL</td><td colspan="1" rowspan="1">545 mg/dL264 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Dade® ThrombinReagent</td><td colspan="1" rowspan="1">Pathological(Low)NormalPathological (High)</td><td colspan="1" rowspan="1">150 mg/dL510 mg/dL500 mg/dL</td><td colspan="1" rowspan="1">20 mg/dL40 mg/dL40 mg/dL</td><td colspan="1" rowspan="1">12 mg/dL29mg/dL60 mg/dL</td><td colspan="1" rowspan="1">171 mg/dL335 mg/dL538 mg/dL</td></tr><tr><td colspan="1" rowspan="1">INNOVANCE®Antithrombin</td><td colspan="1" rowspan="1">NormalHigh</td><td colspan="1" rowspan="1">1000 mg/dL1000 mg/dL</td><td colspan="1" rowspan="1">40 mg/dL40 mg/dL</td><td colspan="1" rowspan="1">60 mg/dL60 mg/dL</td><td colspan="1" rowspan="1">425 mg/dL338 mg/dL</td></tr><tr><td colspan="1" rowspan="1">INNOVANCERD-Dimer</td><td colspan="1" rowspan="1">Normal(Low)NormalPathological (High)</td><td colspan="1" rowspan="1">1000 mg/dL1000 mg/dL1000 mg/dL</td><td colspan="1" rowspan="1">40 mg/dL40 mg/dL40 mg/dL</td><td colspan="1" rowspan="1">60 mg/dL60 mg/dL60 mg/dL</td><td colspan="1" rowspan="1">641 mg/dL300 mg/dL294 mg/dL</td></tr></table>

ii. Additional testing of Hydroxyethyl Starch (HES) was performed for Fibrinogen with Dade $\textsuperscript { \textregistered }$ Thrombin Reagent. For the low and normal plasma pools (i.e. low and normal D-dimer level), interference with HES was observed at an HES level of $2 1 \mathrm { g / L }$ and above. For the high plasma pool, the interference with HES was observed at an HES level of $2 9 \ \mathrm { g / L }$ .

# iii. Prozone testing – D-dimer assay

The only immunochemical reagent measured on the Sysmex CS-5100 coagulation analyzer is D-dimer with INNOVANCE $\textsuperscript { \textregistered }$ D-Dimer reagent. Purified D-dimer was used to spike a plasma sample of an apparently healthy blood donor in order to achieve the concentration of $5 0 0 \mathrm { m g / L }$ FEU. Three replicates were performed for each of the 10 dilutions. All results above the analytical measuring range at a concentration greater than $4 . 4 \ : \mathrm { m g / L }$ FEU are automatically re-diluted by the Sysmex CS-5100 coagulation analyzer.

The intrinsic high dose hook (HDH) algorithm correctly detected potential antigen excess; therefore results were flagged by the instrument at concentrations at and above $1 9 . 1 2 \mathrm { m g / L }$ FEU. The instrument automatically re-diluted the samples to obtain results within the clinically reportable range.

The results of the study confirmed a result of $6 1 1 . 8 4 \mathrm { m g / L }$ FEU, which met the preestablished acceptance criterion that there is no high dose hook effect up to 500 $\mathrm { m g / L }$ FEU.

2. Other Supportive Instrument Performance Data Not Covered Above:

a. Traceability, Stability, Expected values (controls, calibrators, or methods):

i. Traceability: All assay reagents are 510(k) cleared and traceability is specific to reagent performance.   
ii. Reagent stability: All assay reagents are 510(k) cleared and reagent stability studies are specific to reagent performance.   
iii. Sample stability: All assay reagents are 510(k) cleared and sample stability studies are specific to reagent performance.   
iv. On-Board Stability Testing—Reagents: To assess reagent stability during use on the analyzer, an on-board reagent stability study was conducted to establish the maximum on-board stability claims stated in the labeling. A reference value was

measured at the beginning of the study (day 0) by measuring 10 replicates of the individual assay reagent aliquot. Control materials were used as samples. The mean value was determined and was then used as the reference value. Results were analyzed by linear regression analysis. The shortest on-board stability time determined for all samples used with all test batches was then considered the maximum on-board stability time.

v. On-System Stability Testing—Control Material: To assess the on-board stability of commercial control material during use on the Sysmex CS-5100 coagulation analyzer, a stability study was conducted to establish the maximum on-board stability storage claims stated in the labeling. A reference value was measured at the beginning of the study (day 0) by measuring 10 replicates of the individual assay reagent aliquot. The mean value was determined and was then used as the reference value. Three lots of controls were evaluated with at least four replicates of each control. The shortest on-board stability time determined for all samples used with all test batches was then considered the maximum on-board stability time.

vi. Ambient Temperature Testing: The effects of the defined instrument ambient temperature interval, as stated in the instructions for use (IFU) of the Sysmex CS5100 coagulation analyzer, were evaluated. The IFU states the operating environment’s ambient temperature interval is 15 to $3 0 \mathrm { { ^ \circ C } }$ . Plasma pools and controls were tested using one reagent lot at three temperature ranges (15, 22, and $3 0 ^ { \circ } \mathrm { C }$ ) in a temperature controlled environmental chamber. All results met the pre-established acceptance criteria.

# $b$ . Expected values/Reference range:

Clinical studies were performed to quantify reference ranges for the reagent applications for Dade $\textsuperscript { \textregistered }$ Innovin, Dade $\textsuperscript { \textregistered }$ Actin $\textsuperscript { \textregistered }$ FSL, Dade $\textsuperscript { \textregistered }$ Thrombin Reagent, INNOVANCE $\textsuperscript { \textregistered }$ Antithrombin, and INNOVANCE $\textsuperscript { \textregistered }$ D-Dimer. One reagent lot was used for each assay. The reference range is established by calculation of the $9 5 \%$ confidence interval 2.5 – 97.5 percentiles.

<table><tr><td colspan="1" rowspan="1">Application</td><td colspan="1" rowspan="1">Reference Ranges Sysmex CS-5100</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time (seconds) with Dade®Innovin®</td><td colspan="1" rowspan="1">2.5th - 97.5th percentile9.6  12.3</td></tr><tr><td colspan="1" rowspan="1">Prothrombin Time (INR) with Dade®Innovin®</td><td colspan="1" rowspan="1">2.5th - 97.5th percentile0.93 - 1.15</td></tr><tr><td colspan="1" rowspan="1">Activated Partial Thromboplastin Time(seconds) with Dade® Actin® FSL</td><td colspan="1" rowspan="1">2.5th  97.5th percentile23.9  29.9</td></tr><tr><td colspan="1" rowspan="1">Fibrinogen quantitation with Dade®Thrombin Reagent (mg/dL)</td><td colspan="1" rowspan="1">2.5th  97.5th percentile194 - 448</td></tr><tr><td colspan="1" rowspan="1">Antithrombin quantitation withINNOVANCE® Antithrombin (% of norm)</td><td colspan="1" rowspan="1">2.5th  97.5th percentile82.9 - 121.9</td></tr><tr><td>D-dimer quantitation with INNOVANCE®</td><td>2.5th  97.5th percentile</td></tr><tr><td>D-Dimer (mg/L FEU)</td><td>&lt;0.19 - 1.14</td></tr></table>

# c. Detection limit:

Detection capability studies were conducted for Fibrinogen with Dade $\textsuperscript { \textregistered }$ Thrombin Reagent, Antithrombin with INNOVANCE $\textsuperscript { \textregistered }$ Antithrombin reagent and D-dimer with INNOVANCE $\textsuperscript { \textregistered }$ D-Dimer reagent following CLSI document EP17-A2 Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures.

<table><tr><td rowspan=1 colspan=4>Summary of Limit of Quantitation Studies</td></tr><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Lower Limit ofClinical ReportableRange</td><td rowspan=1 colspan=1>Measured Limit ofQuantitation</td><td rowspan=1 colspan=1>Maximum TotalError (%) Result</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen quantitationusing Dade® Thrombin Reagent</td><td rowspan=1 colspan=1>50 mg/dL</td><td rowspan=1 colspan=1>46.1 mg/dL</td><td rowspan=1 colspan=1>16.66%</td></tr><tr><td rowspan=1 colspan=1>Antithrombin quantitationusing INNOVANCE® Antithrombin</td><td rowspan=1 colspan=1>9.0% of norm</td><td rowspan=1 colspan=1>8.783% of norm</td><td rowspan=1 colspan=1>27.34%</td></tr><tr><td rowspan=1 colspan=1>D-dimer quantitationusing INNOVANCE® D-Dimer</td><td rowspan=1 colspan=1>0.19 mg/L FEU</td><td rowspan=1 colspan=1>0.146 mg/L FEU</td><td rowspan=1 colspan=1>31.76%</td></tr></table>

d. Assay cut-off:

The D-dimer assay has a pre-determined cut-off at $0 . 5 \mathrm { m g / L }$ FEU as stated in the reagent package insert.

# e. Lupus sensitivity for APTT

An in-house study of lupus sensitivity was conducted for APTT assay to assess instrument performance. Two lots of APTT reagent and 21 well-defined lupus samples were used in the study. All lupus samples yielded APTT results that exceeded the upper limit of the reference interval for both APTT reagent lots.

# f. Heparin Sensitivity for APTT

Heparin sensitivity study was conducted for APTT assay to assess instrument performance. Samples from patients receiving unfractionated heparin (UFH) therapy were measured with both the Sysmex $\textsuperscript { \textregistered }$ CA-1500 and Sysmex CS-5100 coagulation analyzers using two APTT reagent lots. Passing-Bablok analysis for two lots yielded the following correlation.

In a study comparing APTT using Actin FSL on Sysmex CS-5100 System with Anti Xa testing using Berichrom $\textsuperscript { \textregistered }$ Heparin on Sysmex $\textsuperscript { \textregistered }$ CA-1500 System, a correlation coefficient $\mathbf { r } = 0 . 7 2 1$ was obtained. Classifying the samples using the Anti Xa therapeutic range $( 0 . 3 { - } 0 . 7 \mathrm { I U / m L } )$ and the calculated APTT therapeutic range demonstrated a $34 \%$ discordance level (21 results out of 62 samples were discordant).

# g. Factor Sensitivity for PT and APTT reagents

Factor sensitivity study was conducted for PT and APTT to assess instrument performance. The study used five lots of PT and APTT reagents to test Factor V and Factor VII for PT assay and Factor VIII and Factor IX for APTT assay. The coagulation factor sensitivity level of the PT and APTT assays on the Sysmex CS5100 coagulation analyzer was determined by comparing its results to the lower limit of the respective reference range. Factor sensitivity for five reagent lots yielded:

Factor V: 37 to $50 \%$ Factor VII: 42 to $54 \%$ Factor VIII: 47 to $5 7 \%$ Factor IX: 41 to $49 \%$

# h. Dilution analysis options:

The auto dilution and 4:1 processing mode are analysis features performed automatically by the Sysmex CS-5100 coagulation analyzer where a calibration range was exceeded or where a hook effect for an immunological reagent should be prohibited. Fibrinogen and D-dimer reagent assays are applicable for these two options. A bridging study was performed using three different plasma samples. Samples were tested using manual dilution followed by dilution with the analyzer.

Auto-dilution: Mean results of manually diluted samples were compared to the mean results of the same samples automatically diluted by the analyzers.   
4:1 processing mode: Mean results of undiluted samples were compared to the mean results of the same samples diluted in the auto-dilution mode and 4:1 processing mode.

Deviation was calculated for each dilution analysis option and the results were within $\pm 1 0 \%$ of the pre-defined acceptance criteria.

# i. Normal Mode vs. Micro Mode

A comparison study was conducted in-house to demonstrate equivalence between two modes. Resultant data for PT (seconds), PT (INR), APTT, fibrinogen, Antithrombin, and D-dimer assays were within pre-established acceptance criteria.

# $j .$ . Closed tube vs. open tube performance

A comparison study was conducted in-house to demonstrate equivalence between close tube and open tube modes. Resultant data were within pre-established acceptance criteria.

<table><tr><td rowspan=1 colspan=1>Application</td><td rowspan=1 colspan=1>Passing-Bablok</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Time (seconds) usingDade® Innovin®</td><td rowspan=1 colspan=1>n=182y = 1.000x + 0.000r=1.000</td></tr><tr><td rowspan=1 colspan=1>Prothrombin Time (INR) using Dade®Innovin®</td><td rowspan=1 colspan=1>n=178y = 1.000x + 0.000r = 1.000</td></tr><tr><td rowspan=1 colspan=1>Activated Partial Thromboplastin Timeusing Dade® Actin® FSL</td><td rowspan=1 colspan=1>n=181y = 1.000x + 0.000r= 1.000</td></tr><tr><td rowspan=1 colspan=1>Fibrinogen quantitation using Dade®Thrombin Reagent</td><td rowspan=1 colspan=1>n=170y= 1.000x + 0.000r = 0.998</td></tr><tr><td rowspan=1 colspan=1>Antithrombin quantitation usingINNOVANCE® Antithrombin</td><td rowspan=1 colspan=1>n=179y = 1.000x - 0.300r = 0.999</td></tr><tr><td rowspan=1 colspan=1>D-dimer quantitation usingINNOVANCE® D-Dimer</td><td rowspan=1 colspan=1>n=119y = 1.000x + 0.000r= 1.000</td></tr></table>

# K. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# L. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.